Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model

  title={Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model},
  author={Woong Hahn and Wook Bum Pyun and Dong-Sik Kim and Wonsun Yoo and Sung-Dong Lee and Jung-Hee Won and Gil Ja Shin and Jong‐Mook Kim and Sunyoung Kim},
  journal={The Journal of Gene Medicine},
The therapeutic potential of pCK‐HGF‐X7, a naked DNA designed to express two isoforms of hepatocyte growth factor (HGF723 and HGF728), was studied in the rat ischemic heart disease model. 

A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia

The purpose of the present phase I clinical trial was to evaluate the safety, tolerability, and preliminary efficacy of naked DNA therapy expressing two isoforms of hepatocyte growth factor

Angiogenesis-Based Strategy by Hepatocyte Growth Factor for the Treatment of Ischemic Organ Diseases: From Biology to Clinical Trials

A therapeutic potential of HGF will be discussed, with a focus on biological mechanisms and preclinical or clinical outcomes during ischemic organ diseases.

Effects of Recombinant Adenovirus Hepatocyte Growth Factor Gene on Myocardial Remodeling in Spontaneously Hypertensive Rats

Findings indicate that HGF expression is attenuated in hypertrophic and fibrotic myocardium of SHR and the forced increase in HGF exerts a salutary effect on myocardial fibrosis, collagen I expression, and hemodynamic parameters.

Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy

To evaluate the safety and efficacy of a plasmid (VM202) containing two human hepatocyte growth factor isoforms given by intramuscular injections in patients with painful diabetic neuropathy.

Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia

The data suggest that VM202 is safe and may provide therapeutic bioactivity in CLI patients and significant differences were seen in TcPO2 between the high-dose and placebo groups at 12 months.

Hepatocyte Growth Factor Regulates Macrophage Transition to the M2 Phenotype and Promotes Murine Skeletal Muscle Regeneration

The findings suggested that HGF/c-met might play an important role in the transition of the macrophage during muscle repair, indicating the potential use of HGF as a basis for developing therapeutics for muscle degenerative diseases.

Effective control of neuropathic pain by transient expression of hepatocyte growth factor in a mouse chronic constriction injury model

Data show that pCK‐HGF‐X7 attenuates nerve injury‐induced neuropathic pain by inhibiting pain‐related factors in DRG neurons and subsequent spinal cord glial activation, which suggests its therapeutic efficacy in the treatment of neuropathicPain.

Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study

Intramyocardial injection of VM202 can be safely used in IHD patients with the tolerable dose of 2.0 mg and VM202 might appear to have improved regional myocardial perfusion and wall thickness in the injected region.



Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia

Results showed that transfer of the genomic–cDNA hybrid of the HGF gene could be used as a potential therapeutic approach to human vascular diseases.

Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model.

  • Kwang Ree ChoJae-Sung Choi Ki-Bong Kim
  • Medicine, Biology
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • 2008

Therapeutic angiogenesis using hepatocyte growth factor (HGF).

A potential therapeutic strategy using HGF in cardiovascular disease is discussed, which has been demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease.

Gene Transfer of Hepatocyte Growth Factor Attenuates Postinfarction Heart Failure

Hepatocyte Growth Factor gene transfer following a large myocardial infarction results in significantly preserved myocardIAL function and geometry, and is associated with significant angiogenesis and a reduction in apoptosis.

Myocardial Regeneration Therapy for Heart Failure: Hepatocyte Growth Factor Enhances the Effect of Cellular Cardiomyoplasty

Combined therapy may be a promising strategy for the treatment of heart failure caused by myocardial infarction by stimulating angiogenesis, restoring the impaired ECM, and promoting the integration of the dissociated grafted myocytes.

Hepatocyte growth factor and its variant with a deletion of five amino acids are distinguishable in their biological activity and tertiary structure.

Comparing HGF and the deletion variant (dHGF) revealed that the deletion significantly altered the biological activities, solubility, and immunological property of HGF, and the structural change in HGF may be responsible for its altered biological activities andsolubility.

Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease

The initial clinical outcome with HGF gene transfer seems to indicate usefulness as sole therapy for CLI and safe and feasible injection of naked HGF plasmid DNA is safe, feasible, and can achieve successful improvement of ischemic limbs.

Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia

HGF gene therapy is safe and effective for CLI and improved quality of life (QOL) and there were no major safety problems.